Savara to present new data from the phase 3 impala-2 trial of molgramostim inhalation solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at the american thoracic society international conference 2025

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the american thoracic society (ats) international conference taking place may 16-21, 2025, in san francisco, ca. the company will also host an industry theater titled “advances in autoimmune pulmonary alveolar proteinosis (apap)” at the meeting. ats 2025 posters poste.
SVRA Ratings Summary
SVRA Quant Ranking